|View printer-friendly version|
|August 06, 2018 8:00 a.m.|
|Teva Announces Updated Indication and Vial Presentation for GRANIX® (tbo-filgrastim) Injection in United States|
The new vial presentation of the product will be available for use in 300mcg/1mL and 480mcg/1.6mL single-dose vials. The prefilled syringe presentations will continue to be available as well.
“The new pediatric indication and vial presentation of GRANIX expand the range of treatment options that can be of benefit to both patients and healthcare providers,” said Brendan O’Grady, EVP and Head of North America Commercial at Teva.
GRANIX was approved by the
Important Safety Information
Please see Full Prescribing Information for GRANIX here.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the launch and potential benefits of GRANIX®, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
and other factors discussed in our Annual Report on Form 10-K for the
Teva Pharmaceutical Industries Ltd.